Mastitis Market Research Report - Global Forecast till 2027

Global Mastitis Market: Information by Type (Bovine {Contagious Mastitis, Environmental Mastitis and Opportunist Mastitis} and Human {Non-Infectious Mastitis and Infectious Mastitis}), by Treatment (Bovine {Antibiotics and Vaccines} and Human {Pain Relievers and Antibiotics}), by End User (Veterinary Centers and Hospital & Clinics) and by Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/3936-CR | July 2019 | Region: Global | 142 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

The Global Mastitis Market is expected to register a CAGR of 15.07% to reach USD 18,338.80 Million till 2023. Mastitis is an infection in the tissue of one or both mammary glands inside the breast. It usually affects women who are breastfeeding, and it results from a blocked or a plugged duct. In bovine, mastitis is the inflammation of the mammary gland and udder tissue due to bacterial invasion of the teat canal by a variety of bacterial sources present on the farm, and can also occur as a result of chemical, mechanical, or thermal injury to the cow's udder.


The rising cases of breast cancer, increasing rate of pregnancy, and unhygienic barn conditions causing contagious mastitis in bovines across the globe is expected to enhance the market growth. However, the lack of awareness and complications in diagnosis due to similar symptoms of breast cancer & mastitis are projected to curb the growth of the market.


Market Dynamics


Mastitis has been gaining significance in recent years, owing to the rising incidence of breast cancer. For instance, the Breast Cancer Research Foundation estimated that 266,120 new cases of invasive breast cancer were diagnosed in women in 2018 in the US. Similarly, the UK witnessed around 11,563 deaths due to breast cancer in 2016, according to the Cancer Research UK. Whereas, according to the World Cancer Research Fund International, Belgium had the highest rate of breast cancer in women in 2017. Such a vast population suffering from breast cancer boosts market growth during the forecast period.


Global Mastitis Market Share, by Type, 2016 (%)  Mastitis Market


Source: MRFR Analysis


Segmentation


The global mastitis market, by type, has been segmented into bovine and human. Based on treatment, the Mastitis market has been categorized as bovine and human. Based on end user, the mastitis market has been classified as veterinary centers and hospital & clinics.


Asia-Pacific Mastitis Market Share, 2016 (%)  Mastitis Market


Source: MRFR Analysis


Regional Analysis


The global mastitis market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


The Americas is expected to hold the largest share of the global mastitis market. North America is expected to dominate the market, mainly due to the increasing p prevalence of mastitis among the bovine population and increasing incidence of breast cancer in the region.


Europe is expected to account for the second-largest market share during the forecast period. The factors responsible for market growth in this region are advanced treatment facilities, rising government initiatives to promote healthy breastfeeding, and growing healthcare expenditure. For instance, according to Eurostat, Germany spent over EUR 321 billion in 2014.


Asia-Pacific is estimated to be the fastest-growing region in the global market due to the presence of rapidly developing economies such as China, India, and South Korea. Moreover, the vast patient pool of chronic diseases and government initiatives of healthcare reforms will support the growth of the market.


The mastitis market in the Middle East & Africa is expected to grow due to the affordability and accessibility of healthcare.


Key Players


The prominent players in the global Mastitis market are Bayer AG (Germany), Oncothyreon Inc (US), OncoGenex (US), Apthera Inc. (UK), Zoetis Inc. (US), Boehringer Ingelheim GmbH (Germany), Merck Co. & Inc. (US), Astellas Pharma Inc. (Japan), Pfizer Inc. (US), Novartis AG (Switzerland), Sanofi SA (France), and F. Hoffmann-La Roche AG (Switzerland).


Some of the key strategies followed by players operating in the global mastitis market were innovation, product development, and acquisition & mergers.



  • In June 2018, Boehringer Ingelheim announced a 230-million-euro investment in a new Biological Development Centre (BDC) at the company’s research development sites in Biberach Germany.



  • In June 2017, BioNumerik Pharmaceuticals received approval for Tavocept as an investigational new drug with potential for oncology and non-oncology indications.



  • In May 2017, Merck Co. & received FDA approved Keytruda for the treatment of adult and pediatric patients with previously treated unresectable or metastatic, microsatellite instability-high (MSI-H), or mismatch repair deficient, solid tumors.


Market Segmentation


Global Mastitis Market, by Type



  • Bovine

    • Contagious Mastitis

    • Environmental Mastitis

    • Opportunist Mastitis



  • Human

    • Non-Infectious Mastitis

    • Infectious Mastitis




Global Mastitis Market, by Treatment



  • Bovine

    • Antibiotics

    • Vaccines





  • Human

    • Pain Relievers

    • Antibiotics




Global Mastitis Market, by End User



  • Veterinary Centers

  • Hospital & Clinics


Global Mastitis Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Saudi Arabia

    • United Arab Emirates

    • Kuwait

    • Oman

    • Qatar

    • Rest of Middle East




Available Additional Customizations



  • Company Profiles of Other Key Players

    • HIPRA

    • Others



  • Mastitis Market, Industry Trends


Intended Audience



  • Pharmaceutical Companies

  • Research & Development Organizations

  • Veterinary Institutes



Frequently Asked Questions (FAQ) :


Mastitis market projected to grow at approximately 15.7% CAGR during the assessment period (2020-2027).

The valuation of the global mastitis market is estimated to increase to USD 18,338.80 MN by the end of 2023.

Increasing need for better treatments and government funding support for R&D are major tailwinds pushing the growth of the global mastitis market.

North America holds the largest share in the global mastitis market, followed by Europe and the Asia Pacific, respectively.

Novartis AG (Switzerland), Pfizer (U.S.), Oncogenex (U.S.), BioNumerik Pharmaceuticals (U.S.), Apthera Inc. (U.K), Oncothyreon Inc. (US), Bipar Sciences (U.S.), Astellas (Japan), Puma Biotechnology (U.S.), Eli Lilly and Company (U.S.), Sanofi S.A. (U.S.), AstraZeneca (UK), GlaxoSmithKline (U.K), F. Hoffmann-La Roche (Switzerland), Genentech (U.S), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries (Israel), Gilead Sciences, Inc. (U.S.), and Accord Healthcare, Inc. (U.S.), are some of the top players operating in the global mastitis market.

Overview:


Mastitis is an infection in the tissue of one or both mammary glands inside the breast. It usually affects women who are breastfeeding as a result of a blocked duct. Breast cancer is a key risk factor causing the mastitis conditions.  Women affected with breast cancer are at high risk of contracting mastitis. Mastitis condition in women causes swelling, tenderness, and inflammation of the breast tissues.


Rapid changes in lifestyle, eating habits, and changes in the social system over the last few years have accelerated the spread of cancer.  According to the World Cancer Research Fund (WCRF), breast cancer is the most common cancer in women worldwide and the second most common cancer. The WCRF has reported over 2 million new cases of breast cancer in 2018.


In bovines, mastitis causes inflammation of the mammary gland and udder tissue due to bacterial invasion of the teat canal by a variety of bacterial sources present on the farm, and can also occur as a result of chemical, mechanical, or thermal injury to the cow's udder.


Bovine mastitis causes typically due to contagious or environmental pathogens.  Some of the major reasons that cause bovine mastitis are, contaminated instruments used during milking, improperly cleaned milking units, dirty water used to clean udders, and improper and soiled bedding. These reasons direct towards the unhygienic conditions that bovines live.


Rising cases of bovine mastitis causes hefty losses to the dairy industry every year. For instance, the US alone loses an amount over USD 2 billion per year due to the mastitis at herd – level which means 11% of the total US milk production is wasted.


This huge loss can be attributed to the lack of awareness regarding the bovine health and also due to the lack of awareness of losses caused by bovine mastitis. The lack of implementation of routine mastitis prevention and control practices by herd owners also warrants focus on enhancing dairy farmers’ awareness and practice of hygienic milking, regular screening for sub-clinical mastitis, dry cow therapy, and culling of chronically infected cows.


In order to prevent this, governments across the globe are lending strong support to campaigns and initiatives to spread the awareness. Substantial investments by governments in research and development activities are ensuring the discoveries of novel breakthrough medicines and the growth of the pharmaceutical and biotechnology industry.


Developing economies due to their unfledged research and development sector which are unable to address health challenges offer multiple growth and expansion opportunities to the markets players.


Competitive Landscape:


Prominent players operating in the mastitis market include Apthera Inc. (U.K.), BioNumerik Pharmaceuticals Inc. (U.S.), Pfizer Inc. (U.S.), Astellas Pharma Inc. (Japan), Novartis AG (Switzerland), Oncothyreon Inc. (U.S.), Bayer AG (Germany), Merck Co & Inc. (U.S.), Boehringer Ingelheim GmbH (Germany), Sanofi S.A. (France), F. Hoffmann-La Roche Ltd. (Switzerland), Zoetis Inc. (U.S.), and Oncogenex (U.S.).


Segmentation:


The global mastitis market can be segmented by type, treatment, end-user, and region.  On the basis of type, the global mastitis market is segmented into human mastitis and bovine mastitis. By treatment, the mastitis market is segmented into antibiotics, pain relievers, surgery, vaccines, and others. On the basis of end-user, the mastitis market is segmented into hospitals, clinics, veterinary centers, and others.


Regional Analysis:


The Americas region dominates the global mastitis market mainly due to the higher health care expenditures and the increasing prevalence of mastitis among the bovine population. Europe mastitis market stands the second position, globally mainly due to the high prevalence of breast cancer. The mastitis market in the Asia Pacific region is expected to emerge as a promising market, growing rapidly due to the government initiatives of healthcare reforms.

1 Report Prologue

2 Market Introduction

2.1 Definition 19

2.2 Scope of the Study 19

2.3 Research Objective 19

2.4 Assumptions & Limitations 19

2.4.1 Assumptions 19

2.4.2 Limitations 19

2.4.3 Market Structure 20

3 Research Methodology

3.1 Primary Research Methodology 22

3.2 Secondary Research Methodology 24

3.3 Market Size Estimation 25

3.4 Forecast Model 25

4 Market Dynamics

4.1 Introduction 27

4.2 Drivers 28

4.2.1 Rising Cases of Breast Cancer 28

4.2.2 Increasing Rate of Pregnancy 28

4.2.3 Unhygienic Barn Conditions Causing Contagious Mastitis in Bovines 28

4.3 Restraints 29

4.3.1 Lack of Awareness 29

4.3.2 Complications in Diagnosis due to Similar Symptoms of Breast Cancer & Mastitis 29

4.4 Opportunity 29

4.4.1 Entering Developing Economies 29

4.5 Macroeconomics 29

4.5.1 Trends in Mastitis 30

5 Market Factor Analysis

5.1 Porter’s Five Forces Model 32

5.1.1 Bargaining Power of Suppliers 32

5.1.2 Bargaining Power of Buyers 33

5.1.3 Threat of New Entrants 33

5.1.4 Threat of Substitutes 33

5.1.5 Intensity of Rivalry 33

5.2 Value Chain Analysis 34

5.2.1 R&D & Designing 34

5.2.2 Manufacturing 34

5.2.3 Distribution & Sales 34

5.2.4 Post-Sales Services 34

5.3 Investment Opportunities 35

5.4 Price Analysis 35

6 Global Mastitis Market, By Type

6.1 Introduction 37

6.2 Bovine 38

6.2.1 Contagious Mastitis 38

6.2.2 Environmental Mastitis 39

6.2.3 Opportunist Mastitis 39

6.3 Human 40

6.3.1 Non-Infectious Mastitis 40

6.3.2 Infectious Mastitis 41

7 Global Mastitis Market, By Treatment

7.1 Introduction 43

7.2 Bovine 44

7.2.1 Antibiotics 44

7.2.2 Vaccines 44

7.3 Human 45

7.3.1 Pain Relievers 45

7.3.2 Antibiotics 45

8 Global Mastitis Market, By End User

8.1 Introduction 47

8.2 Veterinary Centers 48

8.3 Hospital & Clinics 48

9 Global Mastitis Market, By Region

9.1 Introduction 50

9.2 Americas 51

9.2.1 North America 54

9.2.1.1 US 56

9.2.1.2 Canada 58

9.2.2 South America 60

9.3 Europe 62

9.3.1 Western Europe 64

9.3.1.1 Germany 67

9.3.1.2 France 69

9.3.1.3 UK 71

9.3.1.4 Italy 73

9.3.1.5 Spain 75

9.3.1.6 Rest of Western Europe 77

9.3.2 Eastern Europe 79

9.4 Asia-Pacific 81

9.4.1 Japan 83

9.4.2 China 85

9.4.3 India 87

9.4.4 Australia 89

9.4.5 South Korea 91

9.4.6 Rest of Asia-Pacific 93

9.5 Middle East & Africa 95

9.5.1 Saudi Arabia 97

9.5.2 United Arab Emirates 99

9.5.3 Kuwait 101

9.5.4 Oman 103

9.5.5 Qatar 105

9.5.6 Rest of Middle East 107

10 Competitive Landscape

10.1 Competitive Scenario 110

10.1.1 Introduction 110

11 Company Profiles

11.1 Bayer AG 113

11.1.1 Company Overview 113

11.1.2 Financial Overview 113

11.1.3 Products Offering 114

11.1.4 Key Developments 114

11.1.5 SWOT Analysis 114

11.1.6 Key Strategy 114

11.2 BioNumerik Pharmaceuticals Inc 115

11.2.1 Company Overview 115

11.2.2 Financial Overview 115

11.2.3 Products/Services Offered 115

11.2.4 Key Developments 115

11.2.5 SWOT Analysis 116

11.2.6 Key Strategy 116

11.3 Oncothyreon Inc 117

11.3.1 Company Overview 117

11.3.2 Financial Overview 117

11.3.3 Products/Services Offered 117

11.3.4 Key Developments 117

11.3.5 SWOT Analysis 118

11.3.6 Key Strategy 118

11.4 Oncogenex 119

11.4.1 Company Overview 119

11.4.2 Financial Overview 119

11.4.3 Products/Services Offered 119

11.4.4 Key Developments 119

11.4.5 SWOT Analysis 119

11.4.6 Key Strategy 120

11.5 Apthera Inc. 121

11.5.1 Company Overview 121

11.5.2 Financial Overview 121

11.5.3 Products/Services Offered 121

11.5.4 Key Developments 121

11.5.5 SWOT Analysis 121

11.5.6 Key Strategy 122

11.6 Zoetis Inc 123

11.6.1 Company Overview 123

11.6.2 Financial Overview 123

11.6.3 Products/Services Offered 124

11.6.4 Key Developments 124

11.6.5 SWOT Analysis 124

11.6.6 Key Strategy 124

11.7 Boehringer Ingelheim GmbH 125

11.7.1 Company Overview 125

11.7.2 Financial Overview 125

11.7.3 Products/Services Offered 126

11.7.4 Key Developments 126

11.7.5 SWOT Analysis 126

11.7.6 Key Strategy 126

11.8 Merck Co. & Inc 127

11.8.1 Company Overview 127

11.8.2 Financial Overview 127

11.8.3 Products/Services Offered 128

11.8.4 Key Developments 128

11.8.5 SWOT Analysis 128

11.8.6 Key Strategy 128

11.9 Astellas Pharma Inc 129

11.9.1 Company Overview 129

11.9.2 Financial Overview 129

11.9.3 Products/Services Offered 130

11.9.4 Key Developments 130

11.9.5 SWOT Analysis 130

11.9.6 Key Strategy 130

11.10 Pfizer Inc. 131

11.10.1 Company Overview 131

11.10.2 Financial Overview 131

11.10.3 Products/Services Offered 132

11.10.4 Key Developments 132

11.10.5 SWOT Analysis 132

11.10.6 Key Strategy 132

11.11 Novartis AG 133

11.11.1 Company Overview 133

11.11.2 Financial Overview 133

11.11.3 Products/Services Offered 134

11.11.4 Key Developments 134

11.11.5 SWOT Analysis 134

11.11.6 Key Strategy 134

11.12 Sanofi SA 135

11.12.1 Company Overview 135

11.12.2 Financial Overview 135

11.12.3 Products/Services Offered 136

11.12.4 Key Developments 136

11.12.5 SWOT Analysis 136

11.12.6 Key Strategy 136

11.13 F. Hoffmann-La Roche AG 137

11.13.1 Company Overview 137

11.13.2 Financial Overview 137

11.13.3 Products/Services Offered 138

11.13.4 Key Developments 138

11.13.5 SWOT Analysis 138

11.13.6 Key Strategy 138

12 Appendix

12.1 Discussion Blue Print 140

12.2 References 141

13 List of Tables

TABLE 1 MARKET SYNOPSIS 17

TABLE 2 PRIMARY INTERVIEWS 23

TABLE 3 GLOBAL MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 37

TABLE 4 GLOBAL MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 38

TABLE 5 GLOBAL MASTITIS MARKET FOR BOVINE, BY REGION 2020–2027 (USD MILLION) 38

TABLE 6 GLOBAL MASTITIS MARKET FOR CONTAGIOUS MASTITIS, BY REGION 2020–2027 (USD MILLION) 38

TABLE 7 GLOBAL MASTITIS MARKET FOR ENVIRONMENTAL MASTITIS, BY REGION 2020–2027 (USD MILLION) 39

TABLE 8 GLOBAL MASTITIS MARKET FOR OPPORTUNIST MASTITIS, BY REGION 2020–2027 (USD MILLION) 39

TABLE 9 GLOBAL MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 40

TABLE 10 GLOBAL MASTITIS MARKET FOR HUMAN, BY REGION 2020–2027 (USD MILLION) 40

TABLE 11 GLOBAL MASTITIS MARKET FOR NON–INFECTIOUS MASTITIS, BY REGION 2020–2027 (USD MILLION) 40

TABLE 12 GLOBAL MASTITIS MARKET FOR INFECTIOUS MASTITIS, BY REGION 2020–2027 (USD MILLION) 41

TABLE 13 GLOBAL MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 43

TABLE 14 GLOBAL MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 44

TABLE 15 GLOBAL MASTITIS MARKET FOR ANTIBIOTICS, BY REGION TYPE 2020–2027 (USD MILLION) 44

TABLE 16 GLOBAL MASTITIS MARKET FOR VACCINES, BY REGION 2020–2027 (USD MILLION) 44

TABLE 17 GLOBAL MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 45

TABLE 18 GLOBAL MASTITIS MARKET FOR PAIN RELIEVERS, BY REGION TYPE 2020–2027 (USD MILLION) 45

TABLE 19 GLOBAL MASTITIS MARKET FOR ANTIBIOTICS, BY REGION 2020–2027 (USD MILLION) 45

TABLE 20 GLOBAL MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 47

TABLE 21 GLOBAL MASTITIS MARKET FOR VETERINARY CENTRES, BY REGION 2020–2027 (USD MILLION) 48

TABLE 22 GLOBAL MASTITIS MARKET FOR HOSPITAL & CLINICS, BY REGION 2020–2027 (USD MILLION) 48

TABLE 23 GLOBAL MASTITIS MARKET, BY REGION 2020–2027 (USD MILLION) 51

TABLE 24 AMERICAS MASTITIS MARKET, BY REGION 2020–2027 (USD MILLION) 51

TABLE 25 AMERICAS MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 52

TABLE 26 AMERICAS MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 52

TABLE 27 AMERICAS MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 52

TABLE 28 AMERICAS MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 52

TABLE 29 AMERICAS MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 53

TABLE 30 AMERICAS MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 53

TABLE 31 AMERICAS MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 53

TABLE 32 NORTH AMERICA MASTITIS MARKET, BY COUNTRY 2020–2027 (USD MILLION) 54

TABLE 33 NORTH AMERICA MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 54

TABLE 34 NORTH AMERICA MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 54

TABLE 35 NORTH AMERICA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 55

TABLE 36 NORTH AMERICA MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 55

TABLE 37 NORTH AMERICA MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 55

TABLE 38 NORTH AMERICA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 55

TABLE 39 NORTH AMERICA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 56

TABLE 40 US MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 56

TABLE 41 US MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 56

TABLE 42 US MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 56

TABLE 43 US MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 57

TABLE 44 US MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 57

TABLE 45 US MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 57

TABLE 46 US MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 57

TABLE 47 CANADA MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 58

TABLE 48 CANADA MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 58

TABLE 49 CANADA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 58

TABLE 50 CANADA MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 58

TABLE 51 CANADA MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 59

TABLE 52 CANADA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 59

TABLE 53 CANADA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 59

TABLE 54 SOUTH AMERICA MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 60

TABLE 55 SOUTH AMERICA MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 60

TABLE 56 SOUTH AMERICA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 60

TABLE 57 SOUTH AMERICA MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 60

TABLE 58 SOUTH AMERICA MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 61

TABLE 59 SOUTH AMERICA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 61

TABLE 60 SOUTH AMERICA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 61

TABLE 61 EUROPE MASTITIS MARKET, BY REGION 2020–2027 (USD MILLION) 62

TABLE 62 EUROPE MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 62

TABLE 63 EUROPE MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 62

TABLE 64 EUROPE MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 63

TABLE 65 EUROPE MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 63

TABLE 66 EUROPE MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 63

TABLE 67 EUROPE MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 63

TABLE 68 EUROPE MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 64

TABLE 69 WESTERN EUROPE MASTITIS MARKET, BY COUNTRY 2020–2027 (USD MILLION) 64

TABLE 70 WESTERN EUROPE MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 65

TABLE 71 WESTERN EUROPE MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 65

TABLE 72 WESTERN EUROPE MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 65

TABLE 73 WESTERN EUROPE MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 65

TABLE 74 WESTERN EUROPE MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 66

TABLE 75 WESTERN EUROPE MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 66

TABLE 76 WESTERN EUROPE MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 66

TABLE 77 GERMANY MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 67

TABLE 78 GERMANY MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 67

TABLE 79 GERMANY MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 67

TABLE 80 GERMANY MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 67

TABLE 81 GERMANY MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 68

TABLE 82 GERMANY MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 68

TABLE 83 GERMANY MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 68

TABLE 84 FRANCE MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 69

TABLE 85 FRANCE MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 69

TABLE 86 FRANCE MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 69

TABLE 87 FRANCE MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 69

TABLE 88 FRANCE MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 70

TABLE 89 FRANCE MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 70

TABLE 90 FRANCE MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 70

TABLE 91 UK MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 71

TABLE 92 UK MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 71

TABLE 93 UK MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 71

TABLE 94 UK MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 71

TABLE 95 UK MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 72

TABLE 96 UK MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 72

TABLE 97 UK MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 72

TABLE 98 ITALY MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 73

TABLE 99 ITALY MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 73

TABLE 100 ITALY MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 73

TABLE 101 ITALY MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 73

TABLE 102 ITALY MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 74

TABLE 103 ITALY MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 74

TABLE 104 ITALY MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 74

TABLE 105 SPAIN MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 75

TABLE 106 SPAIN MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 75

TABLE 107 SPAIN MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 75

TABLE 108 SPAIN MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 75

TABLE 109 SPAIN MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 76

TABLE 110 SPAIN MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 76

TABLE 111 SPAIN MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 76

TABLE 112 REST OF WESTERN EUROPE MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 77

TABLE 113 REST OF WESTERN EUROPE MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 77

TABLE 114 REST OF WESTERN EUROPE MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 77

TABLE 115 REST OF WESTERN EUROPE MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 77

TABLE 116 REST OF WESTERN EUROPE MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 78

TABLE 117 REST OF WESTERN EUROPE MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 78

TABLE 118 REST OF WESTERN EUROPE MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 78

TABLE 119 EASTERN EUROPE MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 79

TABLE 120 EASTERN EUROPE MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 79

TABLE 121 EASTERN EUROPE MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 79

TABLE 122 EASTERN EUROPE MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 79

TABLE 123 EASTERN EUROPE MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 80

TABLE 124 EASTERN EUROPE MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 80

TABLE 125 EASTERN EUROPE MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 80

TABLE 126 ASIA-PACIFIC MASTITIS MARKET, BY COUNTRY 2020–2027 (USD MILLION) 81

TABLE 127 ASIA-PACIFIC MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 81

TABLE 128 ASIA-PACIFIC MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 82

TABLE 129 ASIA-PACIFIC MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 82

TABLE 130 ASIA-PACIFIC MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 82

TABLE 131 ASIA-PACIFIC MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 82

TABLE 132 ASIA-PACIFIC MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 83

TABLE 133 ASIA-PACIFIC MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 83

TABLE 134 JAPAN MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 83

TABLE 135 JAPAN MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 83

TABLE 136 JAPAN MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 84

TABLE 137 JAPAN MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 84

TABLE 138 JAPAN MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 84

TABLE 139 JAPAN MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 84

TABLE 140 JAPAN MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 85

TABLE 141 CHINA MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 85

TABLE 142 CHINA MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 85

TABLE 143 CHINA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 85

TABLE 144 CHINA MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 86

TABLE 145 CHINA MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 86

TABLE 146 CHINA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 86

TABLE 147 CHINA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 86

TABLE 148 INDIA MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 87

TABLE 149 INDIA MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 87

TABLE 150 INDIA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 87

TABLE 151 INDIA MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 87

TABLE 152 INDIA MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 88

TABLE 153 INDIA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 88

TABLE 154 INDIA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 88

TABLE 155 AUSTRALIA MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 89

TABLE 156 AUSTRALIA MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 89

TABLE 157 AUSTRALIA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 89

TABLE 158 AUSTRALIA MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 89

TABLE 159 AUSTRALIA MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 90

TABLE 160 AUSTRALIA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 90

TABLE 161 AUSTRALIA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 90

TABLE 162 SOUTH KOREA MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 91

TABLE 163 SOUTH KOREA MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 91

TABLE 164 SOUTH KOREA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 91

TABLE 165 SOUTH KOREA MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 91

TABLE 166 SOUTH KOREA MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 92

TABLE 167 SOUTH KOREA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 92

TABLE 168 SOUTH KOREA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 92

TABLE 169 REST OF ASIA-PACIFIC MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 93

TABLE 170 REST OF ASIA-PACIFIC MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 93

TABLE 171 REST OF ASIA-PACIFIC MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 93

TABLE 172 REST OF ASIA-PACIFIC MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 93

TABLE 173 REST OF ASIA-PACIFIC MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 94

TABLE 174 REST OF ASIA-PACIFIC MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 94

TABLE 175 REST OF ASIA-PACIFIC MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 94

TABLE 176 MIDDLE EAST & AFRICA MASTITIS MARKET, BY REGION 2020–2027 (USD MILLION) 95

TABLE 177 MIDDLE EAST & AFRICA MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 95

TABLE 178 MIDDLE EAST & AFRICA MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 96

TABLE 179 MIDDLE EAST & AFRICA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 96

TABLE 180 MIDDLE EAST & AFRICA MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 96

TABLE 181 MIDDLE EAST & AFRICA MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 96

TABLE 182 MIDDLE EAST & AFRICA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 97

TABLE 183 MIDDLE EAST & AFRICA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 97

TABLE 184 SAUDI ARABIA MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 97

TABLE 185 SAUDI ARABIA MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 97

TABLE 186 SAUDI ARABIA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 98

TABLE 187 SAUDI ARABIA MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 98

TABLE 188 SAUDI ARABIA MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 98

TABLE 189 SAUDI ARABIA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 98

TABLE 190 SAUDI ARABIA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 99

TABLE 191 UNITED ARAB EMIRATES MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 99

TABLE 192 UNITED ARAB EMIRATES MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 99

TABLE 193 UNITED ARAB EMIRATES MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 99

TABLE 194 UNITED ARAB EMIRATES MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 100

TABLE 195 UNITED ARAB EMIRATES MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 100

TABLE 196 UNITED ARAB EMIRATES MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 100

TABLE 197 UNITED ARAB EMIRATES MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 100

TABLE 198 KUWAIT MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 101

TABLE 199 KUWAIT MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 101

TABLE 200 KUWAIT MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 101

TABLE 201 KUWAIT MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 101

TABLE 202 KUWAIT MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 102

TABLE 203 KUWAIT MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 102

TABLE 204 KUWAIT MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 102

TABLE 205 OMAN MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 103

TABLE 206 OMAN MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 103

TABLE 207 OMAN MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 103

TABLE 208 OMAN MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 103

TABLE 209 OMAN MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 104

TABLE 210 OMAN MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 104

TABLE 211 OMAN MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 104

TABLE 212 QATAR MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 105

TABLE 213 QATAR MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 105

TABLE 214 QATAR MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 105

TABLE 215 QATAR MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 105

TABLE 216 QATAR MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 106

TABLE 217 QATAR MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 106

TABLE 218 QATAR MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 106

TABLE 219 REST OF MIDDLE EAST & AFRICA MASTITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 107

TABLE 220 REST OF MIDDLE EAST & AFRICA MASTITIS MARKET FOR BOVINE, BY TYPE 2020–2027 (USD MILLION) 107

TABLE 221 REST OF MIDDLE EAST & AFRICA MASTITIS MARKET FOR HUMAN, BY TYPE 2020–2027 (USD MILLION) 107

TABLE 222 REST OF MIDDLE EAST & AFRICA MASTITIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 107

TABLE 223 REST OF MIDDLE EAST & AFRICA MASTITIS MARKET FOR BOVINE, BY TREATMENT TYPE 2020–2027 (USD MILLION) 108

TABLE 224 REST OF MIDDLE EAST & AFRICA MASTITIS MARKET FOR HUMAN, BY TREATMENT TYPE 2020–2027 (USD MILLION) 108

TABLE 225 REST OF MIDDLE EAST & AFRICA MASTITIS MARKET, BY END–USER 2020–2027 (USD MILLION) 108

14 List of Figures

FIGURE 1 TOP-DOWN & BOTTOM-UP APPROACHES 25

FIGURE 2 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL MASTITIS MARKET 27

FIGURE 3 PORTER’S FIVE FORCES ANALYSIS: GLOBAL MASTITIS MARKET 32

FIGURE 4 VALUE CHAIN: GLOBAL MASTITIS MARKET 34

FIGURE 5 GLOBAL MASTITIS MARKET, BY TYPE 2020 & 2027 37

FIGURE 6 GLOBAL MASTITIS MARKET, BY TREATMENT 2020 & 2027 43

FIGURE 7 GLOBAL MASTITIS MARKET, BY END-USER 2020 & 2027 47

FIGURE 8 GLOBAL MASTITIS MARKET, BY REGION 2020 & 2027 50

FIGURE 9 AMERICAS MASTITIS MARKET SHARE, BY REGION 2020 51

FIGURE 10 NORTH AMERICA MASTITIS MARKET SHARE, BY COUNTRY 2020 54

FIGURE 11 EUROPE MASTITIS MARKET SHARE, BY REGION 2020 62

FIGURE 12 WESTERN EUROPE MASTITIS MARKET SHARE, BY COUNTRY 2020 64

FIGURE 13 ASIA PACIFIC MASTITIS MARKET SHARE, BY COUNTRY 2020 81

FIGURE 14 MIDDLE EAST & AFRICA MASTITIS MARKET SHARE, BY REGION 2020 95

FIGURE 15 GLOBAL MASTITIS MARKET, MARKET SHARE ANALYSIS 2020 (%) 111

Global Mastitis Market Competitive Landscape:


The prominent players in the global mastitis market are Zoetis Inc., Merck Co. & Inc., Boehringer Ingelheim, Eli Lilly and Company, Bayer Animal Health, Astellas Pharma Inc., Sanofi S.A., AstraZeneca, Teva Pharmaceutical, F. Hoffmann-La Roche Ltd and others.


Zoetis Inc. is the holds the largest share for the global mastitis market in 2017. The firm operates through the discovery, development, manufacture, and commercialization of animal health medicines and vaccines. For more than 60 years, the company has been committed to enhancing the health of animals and bringing solutions to our customers who raise and care for them.


Merck Co. & Inc. holds second position in terms of market share in the global mastitis market in 2017. The company operates in the prescription medicines, vaccines, biologic therapies, and animal health products. The company’s operations are principally managed on a products basis and include four operating segments, which are pharmaceutical, animal health, healthcare services, and alliances. The pharmaceutical segment is the only reportable segment. The main focus of the company is to produce innovative medicines for the treatment of cancer.


Boehringer Ingelheim holds third position in terms of market share in the global Mastitis market in 2017. The company is a highly focused research-driven pharmaceutical company. The main focus of the company is to cure diseases with the help of its core R&D expertise. It constantly works to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies, and on science itself.


Astellas Pharma Inc is one of the top 20 global pharmaceutical research companies. Astellas is an expert in turning innovative science into medical solutions that bring value and hope to patients and their families. The main focus of the company is to keep the focus on addressing unmet medical needs and conducting business with ethics and integrity which enables to improve the health of people throughout the Americas and around the world.


Bayer Animal Health operate in a wide range of areas of business including human and veterinary pharmaceuticals, consumer healthcare products, agricultural chemicals and biotechnology products, and high-value polymers. The pharmaceuticals division of the company focuses on prescription products in the areas of cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology, and ophthalmology.


Zoetis Inc., Merck Co. & Inc., are the major companies for mastitis operating on a global scale. The lower market share of Bayer Animal Health can be attributed to fewer products offering, as compared to Microsurgical Instruments and other major players. Major players such as Astellas Pharma Inc., Sanofi S.A., AstraZeneca, Teva Pharmaceutical, F. Hoffmann-La Roche Ltd increase the level of competition in the global mastitis market, as these companies are expected to expand their product portfolios, with the help of other business units, to increase their market share.


Intended Audience



  • Bovine mastitis drug manufacturers

  • Human mastitis drug suppliers

  • Poultry & research laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors